STX-0712 (novel investigational agent for CMML/AML)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-02-09 — A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML): First-in-human, multicenter, open-label Phase 1 trial launched to evaluate safety, PK/PD, and preliminary efficacy of STX-0712 in patients with advanced CMML or AML who have exhausted standard therapy options (trial-early). (novelty: 4)
Open questions
Related
Contributing findings
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
09-feb-2026
novelty 4
per-area 4
introduces